Actively Recruiting
Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
Led by Murdoch Childrens Research Institute · Updated on 2026-04-08
232
Participants Needed
7
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being conducted at seven major children's hospitals in Australia and New Zealand to test a new approach for treating a virus, called cytomegalovirus in children with weakened immune systems. The researchers want to find out if using a web app to customise the dose of a medication called ganciclovir is better at clearing the virus over a six-week period compared to the standard method of giving the medication.
CONDITIONS
Official Title
Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Immunocompromised patients including transplant recipients (haematopoietic stem cell transplant, solid organ transplant), those receiving chemotherapy or other immunosuppression, or those with a known or suspected inborn error of immunity determined by an immunologist
- Detectable clinically significant cytomegalovirus viraemia with clinician decision that antiviral therapy is needed
- Willing to participate in the trial
- Willing and able to attend all follow-up visits and complete all trial assessments
- Legally acceptable parent or guardian able to provide consent for the participant
- Treating clinician agrees to the child's enrolment in the trial
You will not qualify if you...
- Current or prior CMV infection with documented genotypic resistance to ganciclovir (UL97 and/or UL54)
- Severe renal impairment with estimated glomerular filtration rate less than 25 mL/min
- Congenital CMV infection
- Life expectancy less than 7 days as determined by the treating physician
- History of allergy or adverse reaction to ganciclovir, aciclovir, or any component of the drug formulation
- Treating clinician determines combination antiviral therapy is needed for CMV infection
- Received more than 3 days of IV ganciclovir, foscarnet, or oral valganciclovir before enrolment
- Prior enrolment in this trial
- Currently receiving another investigational product for CMV infection as part of a clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Sydney Children's Hospital
Sydney, New South Wales, Australia, 2031
Actively Recruiting
2
The Children's Hospital at Westmead
Sydney, New South Wales, Australia, 2145
Actively Recruiting
3
Queensland Children's Hospital
Brisbane, Queensland, Australia, 4101
Actively Recruiting
4
The Royal Children's Hospital
Melbourne, Victoria, Australia, 3052
Actively Recruiting
5
Monash Children's Hospital
Melbourne, Victoria, Australia, 3168
Actively Recruiting
6
Perth Children's Hospital
Perth, Western Australia, Australia, 6009
Actively Recruiting
7
Starship Children's Hospital
Auckland, North Island, New Zealand, 1023
Actively Recruiting
Research Team
A
Alice Lei
CONTACT
S
Sharelle Joseland
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here